A1 Medical Imaging’s CEO Compares Magnetic Resonance Imaging (MRI) and Ultrasound Technologies

Peter Solodko, the CEO of A1 Medical Imaging, compares the technological differences between magnetic resonance imaging (MRI) and ultrasound technologies to help determine when one imaging approach is more appropriate than the other.

An ultrasound device gives off high-frequency sound waves that go through the body and creates images called sonograms. As the sound waves bounce off organs and structures, echoes are created. The machine generates the echoes into real-time images on a computer screen that can show the organs, movement, and blood flow. Ultrasound is commonly used to monitor pregnant women and their unborn babies. It is also used to guide a needle to do a biopsy or injection. The technology is non-invasive and does not emit radiation.

MRI is also noninvasive and does not involve radiation. It uses powerful magnets, radio waves and computers to obtain highly detailed, cross-sectional images of various parts of the body. It is used to investigate and diagnose conditions that affect soft tissue such as tumors, certain cancers, and joint, spinal, and ligament injuries and disease. It is commonly used to determine the extent of injury or disease of internal organs such as the brain and in the digestive system.

AI Medical Imaging CEO Peter Solodko“Ultrasound may be good at producing soft tissue images that don’t show up on X-rays,” Peter Solodko indicated. “However, it is limited in some parts of the body because the sound waves can’t go through air, such as the lungs, or through bone.”

MRI is a preferred technology for conditions that involve dense or large areas, while ultrasound can only view one small section at a time. Ultrasound images are not as detailed as MRI scans and cannot show whether a tumor is cancerous.

“Ultrasounds allow clinicians to observe what happens during movement, to see blood flow through arteries, for example,” Solodko explained. “But ultrasounds can’t show the structure inside joints. Because of that, MRI is the better choice to evaluate bone, cartilage and other structures inside and around a joint.”

“There are clear criteria regarding when to use either technology,” Peter Solodko concluded. “It’s up to the referring physician to determine which procedure is best given the individual patient’s situation.”

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.